MARLBOROUGH, Mass., Mar. 5, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the first enrollments in a clinical study evaluating use of the HeartLight X3 System in an early persistent AFib patient population. The 60 patient, prospective study will be led by Na Homolce Hospital (NHH) […]
CardioFocus® Completes Enrollment In HeartLight® X3 Trial
MARLBOROUGH, Mass., Nov. 29, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced completed enrollment in a trial to evaluate its next-generation HeartLight® X3 Endoscopic Ablation System.
CardioFocus® Announces Full Commercial Launch of HeartLight® System in Japan
MARLBOROUGH, Mass., July 11, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for atrial fibrillation (AF), today announced the commercial launch of its HeartLight Endoscopic Ablation System in Japan. The commercial launch will be managed in conjunction with its distribution partner JapanLifeline Co., Ltd. (JLL).
CardioFocus® Announces Successful Live Case Featuring HeartLight® X3 System
MARLBOROUGH, Mass., May 9, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced a successful live case featuring its breakthrough HeartLight X3 System during the annual Prague Workshop on Catheter Ablation.
MARLBOROUGH, Mass., May 7, 2018 /PRNewswire/ — CardioFocus, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of paroxysmal atrial fibrillation (PAF)*.
CardioFocus® Announces Initiation of HeartLight® X3 Clinical Evaluation
MARLBOROUGH, Mass., February 26, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced the initiation of a clinical evaluation of the new HeartLight X3 System for the treatment of AF.
CardioFocus® Announces Expanded Partnership With Japan Lifeline
MARLBOROUGH, Mass., January 9, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced that it has entered into an expanded partnership with Japan Lifeline Co., Ltd. (JLL).
CardioFocus® Completes Successful Controlled U.S. Commercial Launch Of The HeartLight® System
MARLBOROUGH, Mass., November 29, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the successful completion of its controlled U.S. commercial launch of the HeartLightEndoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF).
MARLBOROUGH, Mass., September 27, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the European CE Mark approval of the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of atrial fibrillation (AF).
MARLBOROUGH, Mass., July 31, 2017 /PRNewswire/ — CardioFocus, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved the HeartLight Endoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF) in Japan.